Partner news

Home > Media > Our news > Partner news

Partner news

08 May 2013	Nimbus Discovery announces agreement with Shire to co-develop therapies for rare diseases
07 Jan 2013	Ethris announces research based alliance on SNIM® modified RNA with Shire
07 Jan 2013	ArGEN-X expands its therapeutic antibody alliance with Shire
18 Dec 2012	Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
29 Feb 2012	arGEN-X enters into a therapeutic antibody alliance with Shire
09 May 2011	Heptares Grants Shire an Exclusive Option to License Novel Adenosine A_2A Antagonist
24 Aug 2009	Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders
09 Apr 2009	DSM announces long-term supply agreement with Shire
30 Mar 2009	Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of AmigalTM for Fabry Disease at ACMG 2009 Annual Meeting
04 Aug 2008	Noven Announces Triggering of $25million DAYTRANA® Sales Milestone
24 Oct 2007	Shire Chooses Capgemini as Global IT Partner
11 Oct 2007	Renovo wins European Biotechnica Award 2007
20 Apr 2007	Yale University School of Medicine - Brain Networks Strengthened by Closing Ion Channels (21KB PDF)
21 Feb 2007	NOVEN RECEIVES $25 MILLION DAYTRANA™ SALES MILESTONE
14 Feb 2007	Launch of " Replagal® 3.5 mg "for Anderson-Fabry Disease in Japan

Our global reach

Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.

Our locations

News

Keep up to speed with Shire's latest news by checking out our press release section.

Press releases

Shire Worldwide

Media

Partner news

News

Links

Legal